NasdaqGS - Nasdaq Real Time Price USD
AN2 Therapeutics, Inc. (ANTX)
As of 1:09 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.38 | -0.26 | -1.69 | -1.16 |
| Low Estimate | -0.42 | -0.34 | -1.81 | -1.44 |
| High Estimate | -0.32 | -0.2 | -1.6 | -1 |
| Year Ago EPS | -0.65 | -0.57 | -2.74 | -1.69 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.63 | -0.75 | -0.62 | -0.59 |
| EPS Actual | -0.65 | -0.57 | -0.56 | -0.48 |
| Difference | -0.02 | 0.18 | 0.06 | 0.11 |
| Surprise % | -3.20% | 24.00% | 9.70% | 18.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.38 | -0.26 | -1.69 | -1.16 |
| 7 Days Ago | -0.38 | -0.26 | -1.69 | -1.16 |
| 30 Days Ago | -0.38 | -0.26 | -1.69 | -1.16 |
| 60 Days Ago | -0.37 | -0.29 | -1.7 | -1.22 |
| 90 Days Ago | -0.64 | -0.64 | -2.43 | -2.39 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ANTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 41.50% | -- | -- | 5.10% |
| Next Qtr. | 54.40% | -- | -- | 11.80% |
| Current Year | 38.30% | -- | -- | 2.10% |
| Next Year | 31.40% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | JMP Securities: Market Outperform to Market Outperform | 8/9/2024 |
| Upgrade | Leerink Partners: Market Perform to Outperform | 7/3/2024 |
| Maintains | Evercore ISI Group: In-Line to In-Line | 5/16/2024 |
| Upgrade | JMP Securities: Market Perform to Market Outperform | 4/2/2024 |
| Reiterates | Oppenheimer: Perform to Perform | 4/1/2024 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 2/13/2024 |
Related Tickers
BOLT Bolt Biotherapeutics, Inc.
0.6542
+3.07%
HLVX HilleVax, Inc.
1.8650
+3.04%
ASMB Assembly Biosciences, Inc.
17.23
+2.50%
ALVR AlloVir, Inc.
0.9400
+1.06%
SEER Seer, Inc.
1.8900
-0.53%
TBPH Theravance Biopharma, Inc.
8.30
+0.75%
ACHL Achilles Therapeutics plc
1.0000
-0.50%
SPRB Spruce Biosciences, Inc.
0.5494
+3.43%
OKUR OnKure Therapeutics, Inc.
16.52
-5.60%
GLTO Galecto, Inc.
7.10
+3.65%